About this trial

Colorectal polyp size is related to the risk of exhibiting advanced histological features. Moreover, polyps larger than 10 mm are associated with an elevated risk of metachronous advanced neoplasia and colorectal cancer (CRC). Consequently, accurate measurement of polyp size, especially at the 10 mm threshold is critical for risk stratification and surveillance intervals. Furthermore, polyp size is also important for the choice of the appropriate resection procedures. Underestimation may lead to delayed diagnosis, thereby increasing the risk of colorectal cancer, while overestimation may result in unnecessary surveillance endoscopies.

Eligibility criteria

Qualifiers

They have received colonoscopy for screening, surveillance or symptom investigation;

Aged 18 years older or above;

Written informed consent obtained.

Disqualifiers

Contraindication to colonoscopy (e.g. intestinal obstruction or perforation)

Contraindication or conditions precluding polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets)

Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above)

Trial design

Treatments tested in this trial

  • EndoAIM

Treatment groups

278 Participants
are divided into 1 treatment group

Locations

1
Prince of Wales Hospital Shatin Hong Kong

Sponsors and collaborators

Chinese University of Hong Kong

Lead sponsor